Last reviewed · How we verify
Furosemide Injection
Furosemide Injection, marketed by Johannes Grand, is a pediatric formulation indicated for the treatment of edema, currently holding a position in the market with a key composition patent expiring in 2028. The drug's primary strength lies in its specific indication for pediatric patients, addressing a niche but critical patient population. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic formulations.
At a glance
| Generic name | Furosemide Injection |
|---|---|
| Also known as | Oral Lasix, salbutamol inhalation, Furosemide, G5, 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid |
| Sponsor | Johannes Grand |
| Drug class | Loop Diuretic [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Edema in pediatric patients
- Edema in adults with chronic heart failure
- Edema in adults with chronic kidney disease
Common side effects
- Erythema
- Bruising
- Edema
- Infusion site pain
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Dizziness
- Headache
- Tinnitus
- Hearing loss
Serious adverse events
- Anaphylactic or anaphylactoid reactions with shock
- Toxic epidermal necrolysis
- Stevens-Johnson Syndrome
- Aplastic anemia
- Agranulocytosis
- Interstitial nephritis
- Necrotizing angiitis
- Systemic vasculitis
- Pancreatitis
- Jaundice (intrahepatic cholestatic)
Drug interactions
- Aminoglycoside antibiotics
- Ethacrynic acid
- Salicylates
- Cisplatin
- Nephrotoxic drugs
- Lithium
- Renin-angiotensin inhibitors
- Adrenergic blocking drugs
- Drugs undergoing renal tubular secretion
Key clinical trials
- A Protocol Based-Furosemide Stress Test to Evaluate Renal Recovery During Continuous Renal Replacement Therapy (PHASE4)
- Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers (PHASE1)
- Comparison of Plasma Neutrophil Gelatinase-Associated Lipocalin (pNGAL) Level in De-resuscitation With Furosemide Group and Control Group (NA)
- 18F-DOPA II - PET Imaging Optimization (PHASE3)
- Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure (PHASE3)
- Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser (PHASE3)
- Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients (PHASE4)
- Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Furosemide Injection CI brief — competitive landscape report
- Furosemide Injection updates RSS · CI watch RSS
- Johannes Grand portfolio CI